Oral Antidiabetic Agents refer to the oral drugs used to treat type 2 diabetes in patients who uncontrolled by diet and exercise. Currently, there are five distinct classes of hypoglycemic agents available include sulfonylureas, meglitinides, biguanides, thiazolidinediones and alpha-glucosidase inhibitors.
In 2018, the global Oral Antidiabetic Agents market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Oral Antidiabetic Agents status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Oral Antidiabetic Agents development in United States, Europe and China.

The key players covered in this study
Novo Nordisk
Eli Lilly
Sanofi
Roche
Teva
AstraZeneca
Wockhardt UK
Merck
Pfizer
Cipla

Market segment by Type, the product can be split into
Sulfonylureas
Meglitinides
Biguanides
Thiazolidinediones
Alpha-glucosidase Inhibitors

Market segment by Application, split into
Home Use
Medical Institutions
Others

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Oral Antidiabetic Agents status, future forecast, growth opportunity, key market and key players.
To present the Oral Antidiabetic Agents development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Oral Antidiabetic Agents are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.